• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Dupilumab safe, effective in long-term pediatric use


Improvements in atopic dermatitis symptoms were seen in children taking dupilumab, with minimal adverse events.

Dupilumab (Dupixent; Sanofi and Regeneron) is safe and effective in treating atopic dermatitis (AD) in pediatric patients, according to a recent review.

Trials have proven dupilumab to be safe and effective for pediatric use, but proper analysis of real world dupilumab use has not been recorded.

To determine the long-term efficacy of dupilumab, researchers gathered medical records from March 2017 to September 2022 of pediatric patients with moderate to severe AD.

Information on patients’ demographics, body surface area (BSA), Eczema Area and Severity Index (EASI), and Investigator's Global Assessment (IGA) were collected.

Almost 90 patients were observed, and all saw a 75% improvement in EASI after at least 1 year of dupilumab use, with about 60% of patients seeing a 90% improvement.

Improvements were also seen in BSA and IGA. Patients with a positive history of atopy saw a greater improvement in BSA from weeks 12 to 24.

Adverse events were seen in about 14% of patients, with the most common being conjunctivitis and joint pain. No serious adverse events were observed.


Pagan AD, David E, Ungar B, Ghalili S, He H, Guttman-Yassky E. Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: areal-world, single-center study. J Allergy Clin Immunol Pract. 2022;10(9):2378-2385. doi: 10.1016/j.jaip.2022.06.014

Related Videos
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
Rupa Wong, MD | Image Credit: Rupa Wong, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
John Bradley, MD
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe
Related Content
© 2024 MJH Life Sciences

All rights reserved.